Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on discovery, development, and commercialization of targeted protein degradation medicines for cancer and inflammatory diseases. Its wholly owned pipeline includes bexobrutideg (BTK degrader), zelebrudomide (BTK/IKZF1/IKZF3 degrader), and NX-1607 (CBL-B inhibitor). Nurix also has partnered programs with Gilead, Sanofi, and Pfizer, powered by its DEL-AI discovery engine integrating machine learning and DNA-encoded library screening.
Q2 FY2026 — expected 2026-09-10
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-01-28 | 2025-11-30 | 0001549595-26-000016 | EDGAR | 116K words |
| 2025-01-28 | 2024-11-30 | 0001549595-25-000016 | EDGAR | 115K words |
| 2024-02-15 | 2023-11-30 | 0001549595-24-000025 | EDGAR | 106K words |
| 2023-02-09 | 2022-11-30 | 0001549595-23-000021 | EDGAR | 107K words |
| 2022-01-28 | 2021-11-30 | 0001564590-22-003007 | EDGAR | — |
| 2021-02-16 | 2020-11-30 | 0001564590-21-006071 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-10-09 | 2025-08-31 | 0001549595-25-000113 | EDGAR | 75K words |
| 2025-07-09 | 2025-05-31 | 0001549595-25-000095 | EDGAR | 75K words |
| 2025-04-08 | 2025-02-28 | 0001549595-25-000055 | EDGAR | 73K words |
| 2024-10-11 | 2024-08-31 | 0001549595-24-000131 | EDGAR | 72K words |
| 2024-07-11 | 2024-05-31 | 0001549595-24-000098 | EDGAR | 71K words |
| 2024-04-10 | 2024-02-29 | 0001549595-24-000049 | EDGAR | 69K words |
| 2023-10-12 | 2023-08-31 | 0001549595-23-000048 | EDGAR | 66K words |
| 2023-07-13 | 2023-05-31 | 0001549595-23-000040 | EDGAR | 65K words |
| 2023-04-13 | 2023-02-28 | 0001549595-23-000032 | EDGAR | 64K words |
| 2022-10-06 | 2022-08-31 | 0001564590-22-033709 | EDGAR | — |
| 2022-07-07 | 2022-05-31 | 0001564590-22-025450 | EDGAR | — |
| 2022-04-08 | 2022-02-28 | 0001564590-22-013988 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-06 | 0001193125-26-096734 | EDGAR | 1K words |
| 2026-01-28 | 0001549595-26-000013 | EDGAR | 4K words |
| 2026-01-12 | 0001549595-26-000003 | EDGAR | 3K words |
| 2025-12-09 | 0001549595-25-000121 | EDGAR | 2K words |
| 2025-11-10 | 0001549595-25-000117 | EDGAR | 1K words |
| 2025-10-22 | 0001193125-25-246964 | EDGAR | 1K words |
| 2025-10-22 | 0001549595-25-000115 | EDGAR | 5K words |
| 2025-10-09 | 0001549595-25-000112 | EDGAR | 3K words |
| 2025-09-03 | 0001549595-25-000108 | EDGAR | 1K words |
| 2025-08-22 | 0001549595-25-000105 | EDGAR | 1K words |
113 total filings indexed. 85 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001549595 |
| Ticker | NRIX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.nurixtx.com |
| Listed | 2020-07-24 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/NRIX (~200 tokens, structured JSON with cryptographic provenance)